8-K: Abbott Reports Strong Q4, Full-Year 2025 Results; Issues 2026 Outlook

Abbott announced robust fourth-quarter and full-year 2025 financial results, driven by strong Medical Devices and Established Pharmaceuticals growth, alongside an optimistic 2026 outlook.

Summary

• Fourth-quarter 2025 GAAP diluted EPS was $1.01, while adjusted diluted EPS reached $1.50, reflecting a 12 percent growth.
• Full-year 2025 GAAP diluted EPS was $3.72, and adjusted diluted EPS was $5.15, representing a 10 percent growth.
• Fourth-quarter sales increased 4.4 percent on a reported basis to $11.459 billion, with organic sales growth of 3.0 percent, or 3.8 percent when excluding COVID-19 testing-related sales.
• Full-year 2025 sales totaled $44.328 billion, a 5.7 percent increase on a reported basis, with organic sales growth of 5.5 percent, or 6.7 percent when excluding COVID-19 testing-related sales.
• Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
• Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint.
• The company expects the acquisition of Exact Sciences to close in the second quarter of 2026, positioning it in the cancer diagnostics market.
• Abbott received U.S. FDA approval for its Volt PFA System and CE Mark for its TactiFlex Duo Ablation Catheter, enhancing its Electrophysiology leadership.
• Medical Devices sales increased 12.3 percent on a reported basis and 10.4 percent on an organic basis in the fourth quarter, led by double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management.
• Nutrition sales decreased 8.9 percent on a reported basis and 9.1 percent on an organic basis in the fourth quarter, impacted by lower sales volumes and strategic price actions.
• Diagnostics sales decreased 2.5 percent on a reported basis and 3.6 percent on an organic basis in the fourth quarter, primarily due to declining COVID-19 testing-related sales ($89 million in Q4 2025 vs. $176 million in Q4 2024) and challenging market conditions in China.
• Established Pharmaceuticals sales increased 9.0 percent on a reported basis and 7.0 percent on an organic basis in the fourth quarter, driven by double-digit growth in India and several countries across Latin America and the Middle East.

Sentiment

Score: 8

Explanation: The filing reports strong financial performance with double-digit adjusted EPS growth, robust sales in key segments, strategic acquisitions, and positive future guidance, despite some declines in Nutrition and Diagnostics (due to reduced COVID-19 testing).

Positives

• Achieved double-digit adjusted diluted EPS growth for both the fourth quarter (12 percent) and full-year 2025 (10 percent).
• Projected strong full-year 2026 organic sales growth in the range of 6.5% to 7.5% and adjusted diluted EPS growth of 10 percent at the midpoint.
• Medical Devices segment demonstrated robust performance with 12.3 percent reported and 10.4 percent organic sales growth in Q4 2025.
• Diabetes Care, specifically continuous glucose monitors, reported sales of $2.0 billion, growing 15.0 percent on a reported basis and 12.2 percent on an organic basis in Q4 2025.
• Established Pharmaceuticals segment showed strong growth of 9.0 percent reported and 7.0 percent organic in Q4 2025, with key emerging markets leading with double-digit growth.
• The agreement to acquire Exact Sciences is expected to close in Q2 2026, positioning the company for leadership in the fast-growing cancer diagnostics market.
• Received significant regulatory approvals for new products, including U.S. FDA approval for the Volt PFA System and CE Mark for the TactiFlex Duo Ablation Catheter, expanding Electrophysiology offerings.
• Increased its dividend payout for 54 consecutive years, maintaining its status as a member of the S&P 500 Dividend Aristocrats Index.

Negatives

• Nutrition sales decreased 8.9 percent on a reported basis and 9.1 percent on an organic basis in Q4 2025, attributed to lower sales volumes and strategic price actions.
• Diagnostics sales decreased 2.5 percent on a reported basis and 3.6 percent on an organic basis in Q4 2025.
• COVID-19 testing-related sales significantly declined to $89 million in Q4 2025 from $176 million in Q4 2024, and to $297 million for full-year 2025 from $747 million in full-year 2024.
• Challenging market conditions in China, including the impact of volume-based procurement programs, partially offset growth in Core Laboratory Diagnostics in other geographies.

Risks

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated.
• Economic, competitive, governmental, technological, and other factors that may affect operations are discussed in Item 1A, 'Risk Factors' in the Annual Report on Form 10-K for the year ended Dec. 31, 2024.
• Challenging market conditions in China, including volume-based procurement programs, pose a risk to Diagnostics sales.
• Inability to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact GAAP results.

Future Outlook

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% and adjusted diluted earnings per share of $5.55 to $5.80, reflecting 10 percent growth at the midpoint. First-quarter 2026 adjusted diluted earnings per share is projected to be $1.12 to $1.18. The acquisition of Exact Sciences is expected to close in the second quarter of 2026.

Management Comments

• "In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future." Robert B. Ford, chairman and chief executive officer, Abbott.
• "We're well positioned for accelerating growth in 2026." Robert B. Ford.

Industry Context

Abbott's strong performance in Medical Devices, particularly in Diabetes Care and Electrophysiology, aligns with broader healthcare industry trends focusing on innovative device technologies and chronic disease management. The decline in COVID-19 testing sales reflects the industry-wide shift from a pandemic to an endemic phase. The planned acquisition of Exact Sciences positions Abbott to capitalize on the growing cancer diagnostics market, a key area of strategic focus for many healthcare companies seeking to expand their portfolios in high-growth therapeutic areas.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Includes $165 million for legal reserves related to a certain agreed-upon settlement in Q4 2025.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong financial performance, double-digit EPS growth, positive 2026 outlook, and continued dividend increases, enhancing shareholder value.
• **Customers/Patients**: Positive impact from new product approvals (Volt PFA System, TactiFlex Duo Ablation Catheter) and continued innovation in medical devices and diagnostics, offering advanced healthcare solutions.
• **Employees**: Potential positive impact from company growth and strategic acquisitions, though restructuring actions are mentioned as specified items, which could involve workforce adjustments.
• **Creditors**: Stable outlook due to strong financial health and consistent performance, indicating reliable debt servicing capacity.

Next Steps

• The acquisition of Exact Sciences is expected to close in the second quarter of 2026.
• Launch of several new products in the Nutrition business in 2026 to increase volume growth.
• Abbott will live-webcast its fourth-quarter earnings conference call on January 22, 2026.

Key Dates

Recommendation

The company delivered robust Q4 and full-year 2025 results with double-digit adjusted EPS growth, exceeding expectations. Key segments like Medical Devices and Established Pharmaceuticals showed significant organic growth. The 2026 outlook projects continued strong organic sales and EPS growth, indicating sustained momentum. Strategic moves, such as the Exact Sciences acquisition and new product approvals, position Abbott for future expansion in high-growth markets. The consistent dividend increases further underscore financial strength and commitment to shareholder value. While Nutrition and Diagnostics (ex-COVID) faced headwinds, the overall performance and forward guidance are highly positive, suggesting strong upside potential.

Keywords

Abbott, ABT, Q4 2025 Earnings, Full-Year 2025 Results, 2026 Financial Outlook, Medical Devices, Diagnostics, Nutrition, Established Pharmaceuticals, Electrophysiology, Diabetes Care, Exact Sciences Acquisition, FDA Approval, CE Mark, EPS Growth, Sales Growth, Healthcare